M&A / Deals Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B pharminent April 1, 2026
M&A / Deals Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout pharminent March 31, 2026
M&A / Deals Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy pharminent March 31, 2026
M&A / Deals Biogen, with $5.6B Apellis buy, builds out immunology offerings pharminent March 31, 2026
M&A / Deals Novartis targets Xolair successor in buyout of startup Excellergy pharminent March 27, 2026
M&A / Deals Merck’s deal for Terns sparks debate over a possible biotech bidding war pharminent March 26, 2026
M&A / Deals Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug pharminent March 25, 2026
M&A / Deals Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases pharminent March 24, 2026
M&A / Deals Immutrin raises $87M to advance drug for progressive heart disease pharminent March 24, 2026
